Alimera Sciences Europe Limited (“Alimera”), a wholly owned subsidiary of Alimera Sciences, Inc., and Tanner Pharma UK Limited (“Tanner”) announced today the initiation of a global Named Patient Program for ILUVIEN ® (fluocinolone acetonide intravitreal implant) 0.19 mg for the treatment of diabetic macular edema (DME) and in Europe and the Middle East, for the treatment of non-infectious posterior uveitis (NIU-PS).

Again Life Italia S.r.l. (“ALI”), a pharmaceutical biotechnology company headquartered in Italy, and TannerLAC UK Limited (“TannerLAC”), a wholly owned subsidiary of Tanner Pharma Group and company leader in the Latin American market, announced today the signing of a business partnership agreement for Latin America.

Epimune GmbH, a molecular diagnostic company that develops, manufactures and commercializes in-vitro diagnostic tests for immune cell quantification from a drop of blood, announced today that it has entered into a license agreement with TannerLAC UK Limited ("TannerLAC"), a wholly owned subsidiary of Tanner Pharma Group for the i.Mune TBNK in-vitro diagnostic test in the Latin American region.

Dompé farmaceutici S.p.A. (“Dompé”) and Tanner Pharma Group, Inc. today announced they have entered into an agreement whereby Tanner Pharma Group will become Dompé’s exclusive distribution partner for Oxervate (cenegermin) in selected countries.

Elevar Therapeutics, Inc. ("Elevar"), a late-stage biopharmaceutical company focused on developing and commercializing promising therapies to address unmet needs in cancer, and Tanner Pharma Group ("Tanner"), a global provider of integrated specialty access solutions, today announced a partnership that will facilitate access to Apealea® (micellular paclitaxel) on a named patient basis in areas outside of the United States (U.S.) where Apealea is not commercially available. Apealea has been approved by the European regulatory authorities for use in combination with carboplatin for the treatment of adult patients with first relapse of platinum-sensitive epithelial ovarian cancer, primary peritoneal cancer and fallopian tube cancer.

Tanner Pharma Group, Inc. announced they have partnered with Endo Pharmaceuticals, Inc. to initiate a multi-year Named Patient Program for XIAFLEX® (collagenase clostridium histolyticum), an important nonsurgical treatment option for patients with Dupuytren’s contracture and Peyronie’s disease.

Tanner Pharma Group, a global provider of integrated specialty access solutions, has announced the signing of a distribution agreement with MannKind Corporation, a biopharmaceutical company focused on inhaled therapeutic products for patients with diseases such as diabetes and pulmonary arterial hypertension.

Tanner Pharmaceuticals, Inc., a global pharma services company that provides access to pharmaceuticals through Global Access Programmes and Clinical Trials Sourcing, and BurnsAdler Pharmaceuticals, a specialty pharmaceutical company that licenses and acquires pharmaceuticals, medical devices and over-the-counter (OTC) products for commercialization in Latin America and other international markets, have merged to form Tanner Pharma Group, company officials announced today.